New genetic and epigenetic alterations in the genome discovered by scientists at The Cancer Genome Atlas Research Network offer promising disease markers for acute myeloid leukemia--a finding that may have narrowed the search for drug targets.
A group of investigators say they put one theory related to prostate cancer to the test, and came up with some data indicating it's a dead end for developers as well as doctors looking for the right therapeutic strategy for patients.
The economist Edward Fiedler famously said "He who lives by the crystal ball soon learns to eat ground glass," a statement to whose veracity I can readily attest having written widely on the potential of genomics during my tenure on Wall Street. Read the feature >>
Symphogen has replenished its coffers with 41 million euros ($53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. The latest capital infusion adds to 100 million euros ($130.9 million) that the company previously raised in 2011 for the round, giving the company about 100 million euros in cash as of today, according to the group's press release.
A team of investigators believe they've come up with a convincing profile for a particular type of tumor cell that could be used as a biomarker for diseases progression as well as a target for drug developers looking to identify a next-gen therapeutic.
Scientists at the University of Illinois have used the Cancer Genome Atlas to pinpoint dozens of biomarkers that can gauge a patient's survival prospects with ovarian cancer and also predict when the cancer might return.
In an ambitious effort to find more personalized treatments for cancer and other complex diseases, Oregon Health & Science University in Portland and Intel are teaming up to develop new computing technologies to map an individual's genetic profile more quickly, precisely and cost-effectively.
Scientists have identified multiple metabolic expression changes associated with cancer as well as hundreds of new potential drug targets that could cut off a tumor's fuel supply or interfere with its ability to produce essential building blocks.
Doctors at the University of Mississippi Medical Center accurately gauged whether antiangiogenic treatments are working in melanoma patients by using CT imaging combined with measurements of a key biomarker.
While AstraZeneca's busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the other Cambridge.